Statins and autoimmunity: State-of-the-art.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical and clinical studies without a systematic search or meta-analytic methodology.
PubMed 32592715 · doi:10.1016/j.pharmthera.2020.107614
What was done
This narrative review summarizes experimental and clinical evidence regarding the non-LDL-cholesterol-lowering, immunomodulatory, and anti-inflammatory mechanisms of statins across autoimmune conditions, including rheumatoid arthritis, lupus, and multiple sclerosis.
What was found
The abstract reports no quantitative data, statistics, or effect sizes. It qualitatively reports that statins alter immune function via mevalonate pathway-dependent and -independent mechanisms, impacting cell adhesion, antigen-presenting cell migration, and T-cell activation and differentiation.
Why it matters
If pleiotropic immunomodulatory mechanisms translate into clinical efficacy, statins could potentially serve as adjunctive therapies in managing chronic autoimmune and inflammatory disorders.
Limits
The abstract provides no quantitative outcomes, effect sizes, search methodology, or study counts. As a narrative review, it reflects qualitative synthesis of heterogeneous bench, animal, and clinical literature rather than systematic, pooled evidence.
Cited by
- supports The first statin medication was developed and introduced in 1987.